skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Informa pharma logo

ファーマインテリジェンスはInforma PLCのインフォーマインテリジェンス部門の一部です

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Pharma Intelligence Logo
Search Icon レポートストアメルマガ登録製品ログインProductLogin
Global Search Configuration
  • Close Icon

About Ian

UK

+35 year(s) experience

Ian Schofield
Ian writes for the Pink Sheet, Scrip and In Vivo on a range of issues affecting the life sciences sector, with a focus on regulatory, political, legal and scientific affairs in the EU, Australia, Canada and elsewhere. His articles and analysis provide readers with valuable insights into the significance of regulatory and legislative developments in those markets.
Ian’s specialist areas include biosimilars, generic and orphan drugs, market access, and intellectual property issues. A modern languages graduate, he worked in the European travel industry before joining Scrip in 1985 as a reporter covering the French and Italian markets. He subsequently held posts including Deputy Editor of Scrip and later Principal Analyst at Informa, before taking up his current position. As well as writing news, features and analysis, Ian is part of the Ask the Analyst team that produces on-demand tailored reports for subscribers. His non-work interests include cycling, travel, and playing traditional Scottish music.

Specialties

  • Policy & Regulation
  • Biosimilars
  • Generics
  • Market Access
  • Pricing & Reimbursement

Ian Writes For

Analyst Articles

Articles by Daniel